Obinutuzumab联合氟达拉滨和环磷酰胺治疗初治适合的慢性淋巴细胞白血病患者:GREEN研究亚组分析
GREEN研究(NCT01905943)是一项非随机、开放标签、单臂3b期研究,评估Obinutuzumab单药或联合化疗治疗慢性淋巴细胞白血病(CLL)的安全性和有效性。本文报告了140例初治适合的CLL患者接受Obinutuzumab联合氟达拉滨和环磷酰胺(G-FC)的预设亚组分析。主要终点为安全性和耐受性,疗效为次要终点。
要点
- 87.1%患者发生≥3级不良事件,中性粒细胞减少67.1%,血小板减少17.1%。
- 总缓解率90.0%,完全缓解率46.4%(包括骨髓恢复不完全的CR)。
- 中位观察25.6个月,2年无进展生存率91%。
核心结论
- 一线G-FC是适合的CLL患者的有前景的治疗选择。
研究设计与样本
- GREEN研究(NCT01905943)是一项非随机、开放标签、单臂3b期研究,评估Obinutuzumab单药或联合化疗治疗CLL的安全性和有效性。
- 本报告为预设亚组分析,纳入140例初治适合的CLL患者,接受Obinutuzumab联合氟达拉滨和环磷酰胺(G-FC)治疗。
- 主要终点为安全性和耐受性,疗效为次要终点。
主要发现
- 87.1%患者发生≥3级不良事件,包括中性粒细胞减少67.1%和血小板减少17.1%。
- 42.1%患者发生严重不良事件。
- ≥3级输注相关反应和感染发生率分别为19.3%和15.7%。
- 总缓解率90.0%,完全缓解率46.4%(包括骨髓恢复不完全的CR)。
- 意向治疗分析中,外周血微小残留病阴性率64.3%,骨髓35.7%。
关键数值与推荐
- Obinutuzumab 1000 mg静脉给药,第1周期第1天(剂量分第1-2天)、第8天和第15天,第2-6周期第1天(28天周期)。
- 氟达拉滨和环磷酰胺标准静脉/口服剂量,第1-6周期第1-3天给药。
- 中位观察时间25.6个月,2年无进展生存率91%。
临床怎么用
- 对于初治适合的CLL患者,G-FC方案可考虑作为一线治疗选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
GREEN (NCT01905943) is a nonrandomized, open-label, single-arm, phase 3b study investigating the safety and efficacy of obinutuzumab alone or in combination with chemotherapy in chronic lymphocytic leukemia (CLL). We report the preplanned subgroup analysis of 140 previously untreated, fit CLL patients who received obinutuzumab plus fludarabine and cyclophosphamide (G-FC). The primary endpoint was safety and tolerability. Efficacy was the secondary endpoint. Obinutuzumab 1000 mg was administered intravenously on Day (D)1 (dose split D1‒2), D8 and D15 of Cycle (C)1, and D1 of C2-6 (28-day cycles). Standard intravenous/oral doses of fludarabine and cyclophosphamide were administered on D1-3 of C1-6. Overall, 87.1% of patients experienced grade ≥ 3 adverse events (AEs), including neutropenia (67.1%) and thrombocytopenia (17.1%). Serious AEs were experienced by 42.1% of patients. Rates of grade ≥ 3 infusion-related reactions and infections were 19.3% and 15.7%, respectively. Overall response rate was observed in 90.0%, with 46.4% of patients achieving complete response (CR; including CR with incomplete marrow recovery). Minimal residual disease negativity rates were 64.3% in peripheral blood and 35.7% in bone marrow (intent-to-treat analysis). After a median observation time of 25.6 months, 2 year progression-free survival was 91%. Frontline G-FC represents a promising treatment option for fit patients with CLL.
引用
- Bosch F, Cantin G, Cortelezzi A, et al. Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 2019. PMID: 31455851. doi:10.1038/s41375-019-0554-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。